Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion
You may also be interested in...
Investor Eye: Sofinnova Partners Are Redefining And Disobeying The Venture Investment Commandments
Sofinnova Partners has played an important role in defining the medtech investment space for the past 50 years, helping bring to market a plethora of life-saving technologies, even when they appear, initially, to be risky.
Medtronic Wins Physician-Filed TAVR Patent Suit
The US Court of Appeals for the Federal Circuit upheld a Patent Trial & Appeals Board ruling against a doctor who claimed to be the true inventor of technology used in the CoreValve transcatheter aortic heart valve replacement device.
Direct Flow Taps Lemaitre To Lead Face Off With TAVR Giants
Direct Flow Medical hopes it May 7 appointment of Daniel Lemaitre as CEO will elevate its competitive game against larger players in the transcatheter aortic valve replacement market.